Welcome to our dedicated page for Red Light Hollan news (Ticker: TRUFF), a resource for investors and traders seeking the latest updates and insights on Red Light Hollan stock.
Red Light Holland Corp. reports developments in legal regulated botanical wellness, natural-product therapeutic research, and regulated consumer products. The Ontario-based company owns Filament Health Corp., a clinical-stage natural botanical therapeutics developer with GMP production capabilities, FDA regulatory engagement, a global clinical research footprint, and PEX010, a patented botanical research compound therapeutic candidate.
Company news commonly covers peer-reviewed clinical data, research-institution distribution of PEX010, exclusive licenses to trial data and related intellectual property, and R&D initiatives based on consensual data collection. Updates also address commercial activities in Europe and North America, including regulated consumer product sales in the Netherlands' legal market and home cultivation kits sold through B2B and direct-to-consumer channels.
Red Light Holland (OTCQB: TRUFF) reported Q3 2026 results for the three and nine months ended December 31, 2025, with total cash of $9.238M and revenue of $1.265M for the quarter (up 8.3% year-over-year). Gross profit fell to $0.358M (down 13.7% YoY) while G&A expenses declined 15.8%. The company ceased shiitake production at AEM and is pursuing strategic R&D, M&A evaluations, and distribution growth, including Netherlands truffle sales to over 125 retailers and expanded U.S. retail activity with Albertsons/Safeway.
Red Light Holland (OTCQB:TRUFF) reported Q2 2026 results and a corporate update for the quarter ended September 30, 2025. Key metrics: Revenue $0.754M (down 44.9% YoY), Gross profit $0.327M (down 68.7% YoY), Adjusted EBITDA loss $0.785M (worse 61.9% YoY), Cash $10.226M, Total assets $19.018M.
Operational highlights include expanded U.S. retail distribution with Albertsons/Safeway, new R&D milestones with DEA-registered Irvine Labs (5kg shipment; potency testing compatible with manufacturing), ASU collaboration, and appointment of Dr. Robin Carhart-Harris as scientific advisor. Company pursuing M&A, streamlining, and a Bitcoin allocation up to $2M.
Red Light Holland (OTCQB: TRUFF) announced that its FDA‑compliant, DEA‑registered partner Irvine Labs in California received a second, larger 5 kg shipment of naturally occurring psilocybin imported under a United States Controlled Substances import permit on November 19, 2025.
The shipment was processed under Irvine Labs' 2025 DEA quota after potency testing and process validation confirmed compatibility with medical‑grade manufacturing. The companies said this scale‑up will support expanded R&D toward standardized psilocybin products and clinical/therapeutic programs. The company also issued 3,250,719 common shares at a deemed price of $0.035 per share to arm's length creditors.
Red Light Holland (OTCQB: TRUFF) announced that its wholly owned subsidiary Happy Caps expands distribution with Albertsons Companies' Safeway banner to 123 stores across Oregon and Washington, up from 66 stores, with rollout the week of November 17, 2025 and a replenishment order the week of December 5, 2025 for the holiday season.
Key metrics: 4,428 units to be supplied (up from 2,376), locally produced in Oregon with Trailbridge Mushroom Farm, featuring Shiitake, Lion's Mane, and Oyster home grow kits. The release also discloses equity actions: 100,000 stock options at $0.05, 4,250,000 RSUs, and issuance of 5,611,250 shares to settle debt at $0.035 per share, including related-party RSU and share participation.
Red Light Holland (OTCQB: TRUFF) announced that its FDA‑compliant, DEA‑registered partner Irvine Labs received a second United States Controlled Substances import permit on October 14, 2025, authorizing the import equivalent to 5 kg of psilocybin truffles from Red Light Holland's Netherlands facility.
The company said this follows a Certificate of Analysis confirming psilocybin potency and process validation in September 2025 and will support expanded R&D into dehydration, packaging, shelf‑life extension, and standardized microdosing capsule development for potential medical‑grade manufacturing, government pilot programs, and clinical trials.
Red Light Holland (OTCQB:TRUFF), a producer of functional mushrooms and psilocybin truffles, has achieved a significant milestone by receiving an official Certificate of Analysis (COA) through Irvine Labs, its FDA-compliant and DEA-registered partner in California.
The COA confirms psilocybin potency and process validation for potential medical grade manufacturing applications, following successful testing of naturally derived psilocybin truffles from the company's Netherlands facility. The partnership is advancing proprietary dehydration and packaging processes for extended shelf life while maintaining product integrity.
The company is preparing for a larger planned psilocybin export under Irvine Labs' 2025 DEA quota allocation, targeting emerging therapeutic markets, government-funded pilot programs, and clinical trials.
Red Light Holland (OTCQB:TRUFF) announced a significant expansion of its Happy Caps Mushroom Farm partnership with Safeway. The company's store presence will increase by 86% to 123 locations across Oregon and Washington State, up from the initial 66 stores.
The expanded partnership includes two seasonal programs scheduled for late fall and holiday season 2025, featuring Shiitake, Lion's Mane, and Oyster mushroom home grow kits. The products will highlight "Made in Oregon" and "Certified Organic" certifications, with production through Trailbridge Farms in Oregon to ensure freshness and improved margins.
Red Light Holland (OTCQB: TRUFF) reported its Q1 2026 financial results, showing a revenue of $1.301M, down from $1.559M in Q1 2025, with a gross profit of $0.447M. The company maintained a strong cash position of $11.454M, despite higher cash utilization for debenture payment ($653K) and Bitcoin ETF purchase ($210K).
Notable achievements include entry into the U.S. retail market through Albertsons, launch of Health Canada-approved Functional Mushroom Gummies, and a pilot program with Real Canadian Superstore. The company announced a $2M Bitcoin strategy and partnerships with Irvine Labs and Arizona State University for psychedelic research. SR Wholesale remained cash-positive with steady sales growth in Dutch SmartShops.
Red Light Holland (OTCQB: TRUFF), a company focused on functional mushrooms and psilocybin truffles, has provided an update on its Bitcoin investment strategy. The company has acquired 10,600 shares of iShares Bitcoin ETF (IBIT) at an average cost of C$44.60 per share as part of its C$2 million Bitcoin allocation plan.
The company is also establishing a corporate account with a major exchange to implement algorithmic trading strategies through Arch Public Inc., following the recommendation of Lead Cryptocurrency Advisor Scott Melker. This initiative aims to strengthen the company's treasury while aligning with its vision of innovation and decentralization.
Red Light Holland (OTCQB: TRUFF), a producer of functional mushrooms and magic truffles, has welcomed the DEA's historic decision to forward a psilocybin rescheduling petition to HHS for review. This marks the first-ever advancement of a petition to potentially reclassify psilocybin from Schedule I to Schedule II.
The company, through CEO Todd Shapiro, expressed optimism about the review, highlighting psilocybin's potential therapeutic benefits for anxiety, depression, and PTSD. The rescheduling could enable compassionate use programs, enhanced research development, and future FDA approvals.
Additionally, Red Light Holland reported successful validation of its natural psilocybin truffles through third-party testing at Irvine Labs, confirming their compatibility with potential medical grade manufacturing applications.